Replimune Group (NASDAQ:REPL) Trading Down 6.6% - Here's Why

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) shares traded down 6.6% during mid-day trading on Tuesday . The company traded as low as $10.16 and last traded at $10.17. 382,397 shares were traded during mid-day trading, a decline of 45% from the average session volume of 695,592 shares. The stock had previously closed at $10.89.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Jefferies Financial Group boosted their price target on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 24th. HC Wainwright reiterated a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. Finally, BMO Capital Markets upped their target price on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research report on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $17.29.

Replimune Group Price Performance

The firm has a fifty day moving average of $12.34 and a two-hundred day moving average of $11.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The stock has a market capitalization of $717.69 million, a P/E ratio of -3.44 and a beta of 1.28.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. On average, analysts predict that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in shares of Replimune Group in the 2nd quarter worth approximately $57,000. Arizona State Retirement System acquired a new stake in shares of Replimune Group in the 2nd quarter valued at about $108,000. Quest Partners LLC grew its position in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company's stock worth $122,000 after purchasing an additional 3,150 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Replimune Group during the third quarter worth $133,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock worth $144,000 after purchasing an additional 5,926 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.